/

Sociétés

Da

Non vérifié

Daiichi Sankyo

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

109 communiqués de presse

Voir tous les communiqués de presse

25/09/2026

Industrie

Oncologie

Hygiène alimentaire

Santé

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Source

Émetteur

1.00

0

18/09/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Source

Émetteur

1.00

0

14/09/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Événements

Industrie

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Source

Émetteur

1.00

0

01/09/2026

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Source

Émetteur

1.00

0

28/08/2026

Événements

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Cardiologie

Biotechnologie

Nuovi dati di Daiichi Sankyo evidenziano l'effetto dell'acido bempedoico nella gestione della dislipidemia e del rischio cardiovascolare nella pratica clinica

Source

Émetteur

1.00

0

28/08/2026

Événements

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Cardiologie

Biotechnologie

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk

Source

Émetteur

1.00

0

27/08/2026

Oncologie

Santé

Médecine - Divers

Santé Publique

Industrie pharmaceutique

Biotechnologie

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Source

Émetteur

1.00

0

26/08/2026

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

Source

Émetteur

1.00

0

24/08/2026

Marché du travail

Équipement médical et sanitaire

Santé

Santé Publique

Industrie pharmaceutique

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Source

Émetteur

1.00

0

24/08/2026

Marché du travail

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0